key: cord-0805273-848fswtv authors: Osuchowski, Marcin F.; Aletti, Federico; Cavaillon, Jean-Marc; Flohé, Stefanie B.; Giamarellos-Bourboulis, Evangelos J.; Huber-Lang, Markus; Relja, Borna; Skirecki, Tomasz; Szabó, Andrea; Maegele, Marc title: SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities date: 2020-05-21 journal: Shock DOI: 10.1097/shk.0000000000001565 sha: 94556c5de293bd7fb1665c5988f28caa7c0966e3 doc_id: 805273 cord_uid: 848fswtv Approximately 3 billion people around the world have gone into some form of social separation to mitigate the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The uncontrolled influx of patients in need of emergency care has rapidly brought several national health systems to near-collapse with deadly consequences to those afflicted by Coronavirus Disease 2019 (COVID-19) and other critical diseases associated with COVID-19. Solid scientific evidence regarding SARS-CoV-2/COVID-19 remains scarce; there is an urgent need to expand our understanding of the SARS-CoV-2 pathophysiology to facilitate precise and targeted treatments. The capacity for rapid information dissemination has emerged as a double-edged sword; the existing gap of high-quality data is frequently filled by anecdotal reports, contradictory statements, and misinformation. This review addresses several important aspects unique to the SARS-CoV-2/COVID-19 pandemic highlighting the most relevant knowledge gaps and existing windows-of-opportunity. Specifically, focus is given on SARS-CoV-2 immunopathogenesis in the context of experimental therapies and preclinical evidence and their applicability in supporting efficacious clinical trial planning. The review discusses the existing challenges of SARS-CoV-2 diagnostics and the potential application of translational technology for epidemiological predictions, patient monitoring, and treatment decision-making in COVID-19. Furthermore, solutions for enhancing international strategies in translational research, cooperative networks, and regulatory partnerships are contemplated. The Interferons. The precise role of IFNs in SARS-CoV-2 infection is yet unclear and requires further investigation. It is unclear whether patients by default produce amounts of interferon like certain mammals (84) or low IFN concentrations may reflect the coronaviruses' capacity to prevent/reduce its production and action (85-92). The latter may be plausible given that CoV are well capable of preventing NF-B activation (93) and protein translation (94). It is also important to define the specific role played by IFN-ε in the mucosa; this may explain differences between humans versus bats/pangolins regarding their response to a CoV infection (95-97). Better understanding of the crosstalk between SARS-CoV-2 and IFNs will offer insights into the COVID-19 immunopathogenesis. Some data suggest that the strategy of a very early administration of type I IFN could be considered (98-100). However, the negative effect of a late exposure to IFNs must also be considered; a study combining single-cell RNA-sequencing data and in vitro analysis showed that ACE2 is upregulated by type I and II IFNs in human and primate airway epithelial cells (101). Coagulopathy & endotheliopathy. Coagulopathy appears to be a critical element in the context of severe COVID-19 courses. Elevation of D-dimers (fibrin degradation products) has been frequently observed in severe cases and identified as a significant risk factor (104). One study revealed presence of a procoagulant state even during the early COVID-19 stage (19) and disseminated intravascular coagulation (DIC) has been diagnosed in most critically ill patients (105). Moreover, the incidence of thromboembolic events is high (comparable to sepsis) and most likely underdiagnosed (106). It can be hypothesized that there is dominant local pulmonary vessel microthrombosis which corelates with the severity of hypoxemia and high compliance (107) and stays in accordance with fibrin cumulation found in the lungs (107, 108). Presumably, there are several pathways which may contribute to the clinical coagulopathy observed. Direct infection of the endothelium, thereby triggering endothelial injury, inflammation and cell death (20) , can direcly activate the coagulation cascade. Pyroptosis and inflammasome-released mediators are other potent coagulation cascade activators (109, 110). Histopathological examination revealed deposition of activated complement complexes that may propel microvascular injury and subsequent activation of the clotting pathway (111) . Neutrophilic infiltrates can also activate coagulation through the generation of neutrophil extracellular traps (NETs) (112) and a recent anecdotal study confirmed the presence of antiphospholipid antibodies in three COVID-19 patients with severe coagulopathy (113) . An analysis of over 3,500 genes (differentially expressed in the lungs) following murine SARS-CoV infection identified various pro-coagulatory factors (especially urokinase) to be strongly associated with mortality (114) . Urokinase activity results in the generation of plasmin and in turn in fibrinolysis with elevated D-dimers manifested by alveolar coagulopathy and pulmonary hemorrhage. Furthermore, serpin1 knockout mice confirmed an enhanced pulmonary expression of procoagulatory and profibrinolytic proteins and clinical susceptibility to SARS-CoV (114) . Apart from cytokine effects on the pulmonary endothelium, it has also been proposed that dysruptions of the kallikrein-bradykine axis can increase microvascular permeablity and cause angioedema (115) . The number of proposed therapeutic strategies against COVID-19 grows weekly; presently, there are over fifty substances considered as potential remedies including brand new (siRNA; 119) as well as well-known/repurposed chemicals (chloroquin, interferons, remdesivir). Yet, the currently available pre-and clinical evidence supportive of the experimental therapies is suggestive at best. Several substances with different targets have been proposed based on sparse peer-reviewed publications ( Table 3) ; some based on nonpeer reviewed (medRxiv and bioRxiv) pre-prints and/or anecdotal evidence only. As of April 30, 2020 , no peer-reviewed study has ever tested any anti-COVID-19 candidate drug in a relevant SARS-CoV-2 animal model; many drugs have not yet been directly tested against SARS-CoV-2 in vitro. The only available animal model-based evidence stems from MERS/SARS-CoV studies ( Table 3 ) but these diseases are not identical with COVID-19 (Table 2) . Mechanistically, we are only at the very beginning to understand how SARS-CoV-2 infects, targets the lungs (and other organs) and causes severe vascular and tissue damage. However, small laboratory animals remain the most accessible and cost-effective model to study. Transgenic human ACE-2 mice (both sexes) infected with the HB-01 strain developed COVID-19-like interstitial pneumonia, high viral load, and produced high specific IgG titer but the disease was generally mild (125) . Syrian hamsters constitute another potential option; two groups recently recapitulated a mild but widely symptomatic COVID-19 phenotype (126, 127) . In contrast, species such as pigs, chickens and ducks were virus-free when either inoculated or exposed to the virus, cats were asymptomatic despite post-exposure infection whereas dogs were minimally susceptible to SARS-CoV-2 exposure (128) . Experimental drugs will soon be tested in the newly emerging COVID-19 models. While modeling of SARS-CoV-2 infection in healthy and young animals will be informative, it is important to consider that the most severe COVID-19 phenotypes appear in aged patients with comorbidies -the animal models should reflect this to maximize their translational capability for pathophysiology studies and drug testing. The most recent macaque experiment attests to that; 15-year-old animals developed an exacerbated COVID-19 phenotype while the young ones did not (129) . Another important element in pre-clinical modeling is to promote study designs that allow drug testing in divergent, precisely defined and relatively homogeneous COVID-19 phenotypes (provided they can be recapitulated in animals). It is likely that a given therapeutic may be either beneficial or detrimental contingent upon the timing of its administration and/or specific COVID-19 pathophysiological characteristic. Compared to patients, animal studies present a relatively cheap and safe platform to establish such relationships. The yet limited evidence derived from pre-clinical studies coupled with the emerging clinical data as discussed previously indicate that SARS-CoV-2-induced coagulopathy may be one of the key interests for experimental studies (114) . In this context, another less apparent but interesting target for potential COVID-19 therapy is the complement activation pathway. Genetic absence of the complement C3 component was associated with reduced pulmonary/systemic inflammation and improved lung function (130) . MERS-CoV-infected mice displayed elevated complement component C5a in the lungs and blood and blockade of the C5aR receptor attenuated inflammation in the lungs and spleen and reduced pulmonary viral replication (131 and clinical studies will gradually reveal the cons and pros of the experimental therapeutics. With the exception of remdesivir, which has received an emergency use authorization (EUA) 83%) (158) . This French study was further confirmed by the same team on 80 patients (159) . These studies were heavily criticized by the MRC-NIHR Trials Methodology Research Partnership for numerous shortcomings (158) . The two subsequent studies with hydroxychloroquine indicated no improvement (160, 161) . The most recent reports emphasize risks associated with chloroquine-based trials; due to adverse cardiac reactions, chloroquine treatment (with and without azithromycin) was stopped in Brazilian (162) and French (163) trials; and several hospitals in Sweden stopped administering hydroxychloroquine to COVID-19 patients based on similar findings (164). A recent preprint article that retrospectively analyzed hydroxychloroquine use in hospitalized US veterans found an association of increased overall mortality with its use (165) . (175). An additional major concern of many ongoing COVID-19 trials is their relatively low power to detect significant differences in meaningful outcomes. Low-powered trials rarely provide unequivocal evidence justifying the use of tested therapeutics. In this respect, pandemics provide a unique window of opportunity for large-scale collaborative initiatives, thus, enabling networks to jointly generate and address common goals as well as to standardise data collection in large patient year. The differentiation of the SARS-CoV-2-positive cases from the healthy is among the main clinical challenges. Many asymptomatic persons are a source of infection despite being considered healthy prior to a positive test result (180) . The prevalence of asymptomatic (SARS-CoV-2 positive) patients ranges between 1.5 and 30% (180) (181) (182) . Non-test based COVID-19 diagnosis is difficult given that the most common clinical symptoms, e.g., fever, fatigue, dry cough, myalgia, and dyspnea (48, 183) are unspecific and overlap with other viral diseases (183) . Several hematologic and immuno-inflammatory abnormalities observed in SARS-CoV-2-positive patients resemble MERS/SARS-CoV infection symptoms (183) . To reduce the transmission risk, aggressive containment, mitigation and treatment strategies must be combined and rapid and accurate testing is key. A few countries/territories such as Taiwan, Hong Kong, Singapore and South Korea have rapidly implemented aggressive testing (184) ; South Korea has performed >300,000 tests (5829 tests/million population) within the 9 weeks after the first SARS-CoV-2 case was identified, effectively containing the SARS-CoV-2 spread (185, 186) . The majority of other countries have been struggling with tests approval, availability and/or operationalization of high-throughput testing, which was accompanied by substantial differences in reported numbers. The current recommendation of many professional radiological associations and societies is that imaging should not be employed as a screening nor diagnostic tool for COVID-19 but reserved for the evaluation of complications. Although used frequently in early reports with some characteristic features described (25, Figure 2) (189, 190) . The WHO testing recommendations differ depending on the SARS-CoV-2 prevalence. In the virus-free areas, a positive NAAT for at least two target SARS-CoV-2 genes is considered reliable; in areas with SARS-CoV-2 presence, a confirmation of a single discriminatory target is sufficient (183, 187 (192) . Therefore, a negative RT-PCR result does not necessarily rule out the possibility of SARS-CoV-2 infection (192) . The WHO quotes several culprit factors including a poor specimen quality, timing of specimen collection, specimen handling and/or shipping and various technical problems (187). A small Chinese study demonstrated that some COVID-19 patients who met criteria for hospital discharge and/or quarantine discontinuation (free of clinical symptoms, radiological abnormalities and with two negative RT-PCR tests) were tested positive (by RT-PCR) 5 to 13 days later (193) . A South Korean study reported that two out of ten negative COVID-19 cases by RT-PCR were later confirmed as positive (194) . In a large study, the second RT-PCR test was positive in 12.5% of initially negative 384 patients (195) . Thus, the detection of SARS-CoV-2 is highly specific (no false positives) but the sensitivity is not ideal (196) . These findings reveal limitations of RT-PCR testing and indicate that some recovered patients may continue to be virus carriers (193) . This phenomenon, if confirmed on a larger scale, may force changes in the current criteria for hospital discharge and quarantine discontinuation. Furthermore, the SARS-CoV-2 diagnostics should account for clinical findings; preliminary data from China showed that isolated patients (with presumed COVID-19) with initially negative RT-PCR but with typical clinical and radiological COVID-19 symptoms were confirmed as SARS-CoV-2-positive after repeated swab testing (192) . Thus, a combination of repeated RT-PCR testing and radiological imaging may be helpful in determining suspected false-negative cases. Although the RT-PCR constitutes the current diagnostic standard, the test kits suffer considerable limitations. In 610 patients, in the first all-patient test, 27.5% cases were positive, 0.2% weakly positive, 9.3% dubious and 63% were negative (195) . Among the patients with initial negative results, the second test was positive in 12.5%, dubious in 7% patients, negative in 73% patients, and results were not available for 7.6% patients (195) . The false negative readouts are also contingent on the workflow for molecular detection (e.g. and isolation method with/without commercial kit) (192, 193, 197 Despite its epidemiological and diagnostic potential, it is premature to expect AI to be a game-changer in real-time patient monitoring (214) . It is unclear whether AI can precisely prognosticate, and its usefulness has been modest in the context of therapy design. Even though AI algorithms have been used to predict the efficacy of existing drugs repurposed to treat COVID-19 (215, 216) , the candidate drugs (and pharmacological targets) still require experimental validation before translating them to bedside and into clinical practice. Interestingly, promising results were obtained from the analysis of high-throughput data on the interaction between SARS-CoV-2 and ACE2 receptors encouraging research on interventions preventing the internalization of SARS-CoV-2 (144, 217) . The contribution of data-driven models in the improvement of patient monitoring and in the design of new therapeutic approaches critically depends on the quality of the available data; it is key to ensure the best possible consistency and homogeneity across databases. (229) and neurological manifestations (230) . Retrospective studies will be necessary to build and validate physiological multiscale models. The success of this effort will rely on the availability of well-annotated, cohesive and consistent databases and corresponding biobanks. The integration of statistical (data-driven) modeling and physiological (knowledge-based) modeling should be pursued to enhance the translational potential of computational analytics for: i) diagnostics and monitoring, ii) the design of novel, more effective treatments, iii) the guidance of therapy by decision support systems. The SARS-CoV-2 outbreak has triggered an unprecedented cooperative activity worldwide, continents (https://esicm-tv.org/covid19/). However, perception of the rapid data dissemination by the pre-print servers (e.g. bioRxiv.org; medRxiv.org) is less favorable. There has been a growing concern that such a steep growth of unscrutinized scientific evidence (2492 bio/medRxiv.org articles on SARS-CoV-2/COVID-19; accessed April 30, 2020) rather provokes more confusion than meritorious guidance and indiscriminately selected pieces of the pre-printed data are recurrently sensationalized by the lay press. Despite relatively clear genetic relationships among sampled viruses, an uncertainty for specific transmission dates and the reconstruction of the geographic spread remains. Note, that the specific inferred transmission patterns (connecting lines) are only hypothetical (25) . Thousands of complete genomes are available and increase on a daily basis. The visualization is based upon sub-sampled available genome data (see more under: https://nextstrain.org/ncov). As the pathogen replicates and spreads, its genome is replicated and random mutations/errors accumulate in the genome. Such random mutations allow tracking of the SARS-CoV-2 spread inferrences regarding its transmission routes and dynamics. The colors indicate the origin/source of the various viral strains, while circle diameters reflect the size of the transmission clusters. anti-type I IFN strategies preventing its production and its effects anti-type I IFN strategies preventing its production and its effects unclear; under investigation *Due to the similar origin and genome, the immune response to human coronaviruses shares several confirmed and assumed aspects but numerous differences have already been reported. The characterized immune responses are of relevance to their pathophysiology and treatment (116) (117) (118) . ACE: angiotensin-converting enzyme; CoV: coronavirus; DC: dendritic cell; IFN: interferon; PBMC: peripheral blood mononuclear cell; IL: interleukin; SARS: Severe Acute Respiratory Syndrome; MERS: Middle East Respiratory Syndrome Table 3 . Pre-clinically tested therapeutics against SARS-CoV, MERS-CoV and SARS-CoV-2 and related illness* China Medical Treatment Expert Group for Covid-19: Clinical Characteristics of Coronavirus Disease 2019 in China The Lancet: COVID-19: too little, too late? Delays in Global Disease Outbreak Responses: Lessons from H1N1, Ebola, and Zika Hospital readiness checklist for COVID-19. www.euro.who.int (Retrieved Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 CDC Cruise Ship Response Team; California Department of Public Health COVID-19 Team; Solano County COVID-19 Team: Public Health Responses to COVID-19 Outbreaks on Cruise Ships -Worldwide Virological assessment of hospitalized patients with COVID-2019 Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship Unauthorized reproduction of this article is prohibited SARS-CoV-2 viral load in upper respiratory specimens of infected patients The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective Likelihood of survival of coronavirus disease 2019 Novel Coronavirus Pneumonia Emergency Response Epidemiology Team: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China COVID-19 Coagulopathy in Caucasian patients COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome Endothelial cell infection and endotheliitis in COVID-19 Endothelial dysfunction: a marker of atherosclerotic risk Autopsy in suspected COVID-19 cases Unauthorized reproduction of this article is prohibited Estimates of the severity of coronavirus disease 2019: a model-based analysis Nextstrain: real-time tracking of pathogen evolution Coronavirus disease 2019: Initial chest CT findings A(H1N1) influenza viruses circulating in humans Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1 Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak A Sialylated Voltage-Dependent Ca2+ Channel Binds Hemagglutinin and Mediates Influenza A Virus Entry into Mammalian Cells GLaMOR Collaborating Teams: Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study Unauthorized reproduction of this article is prohibited Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Liver injury during highly pathogenic human coronavirus infections Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong Transmission dynamics and control of severe acute respiratory syndrome High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Unauthorized reproduction of this article is prohibited Clinical and immunologic features in severe and moderate Coronavirus Disease Dysregulation of immune response in patients with COVID-19 in Wuhan, China Viral dynamics in mild and severe cases of COVID-19 Immunologic Effects of the Renin-Angiotensin System Immunologic Effects of the Renin-Angiotensin System China Novel Coronavirus Investigating and Research Team: A Novel Coronavirus from Patients with Pneumonia in China Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome Lactate dehydrogenase, a Risk Factor of Severe COVID-19 Patients Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv Copyright © 2020 by the Shock Society SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development The potential danger of suboptimal antibody responses in COVID-19 Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology An interferon-gammarelated cytokine storm in SARS patients Facing COVID-19 in ICU: vascular dysfunction, thrombosis, and dysregulated inflammation COVID-19: a new virus, but an old cytokine release syndrome Cytokine cascade in sepsis Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Neutrophil extracellular traps in COVID-19 Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury Kinins and Cytokines in COVID-19: A Comprehensive Pathophysiological Approach. Preprints Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia MERS coronavirus in dromedary camel herd Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome The pandemic pipeline Comparison of SARS-CoV-2 infections among 3 species of non-human primates. bioRxiv Copyright © 2020 by the Shock Society Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Infection and Rapid Transmission of SARS-CoV-2 in Ferrets The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice. bioRxiv Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility Pathogenesis and transmission of SARS-CoV-2 virus in golden Syrian hamsters Agerelated rhesus macaque models of COVID-19 Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV Unauthorized reproduction of this article is prohibited Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque Application of siRNA against SARS in the rhesus macaque model An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Unauthorized reproduction of this article is prohibited Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV Pegylated interferon-Copyright © 2020 by the Shock Society. Unauthorized reproduction of this article is prohibited. alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques HKU/UCH SARS Study Group: Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease Asian Critical Care Clinical Trials Group: Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study Unauthorized reproduction of this article is prohibited No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial CloroCovid-19 Team: Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 Compassionate Use of Remdesivir for Patients with Severe Covid-19 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial Unauthorized reproduction of this article is prohibited Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Correction to: Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017 National Influenza A(H1N1)pdm09 Clinical Investigation Group of China: Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease Optimizing the Trade-off Between Learning and Doing in a Pandemic The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Study: Rationale and Design A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above Trial of Treatments for COVID-19 in Hospitalized Adults Unauthorized reproduction of this article is prohibited The COVID-19 vaccine development landscape Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen High incidence of asymptomatic SARS-CoV-2 infection Transmission within a family cluster by presymptomatic infectors in China Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1 Fast, portable tests come online to curb coronavirus pandemic Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Unauthorized reproduction of this article is prohibited COVID-19 Task Force and the Center for Laboratory Control of Infectious Diseases, the Korea Centers for Disease Control and Prevention. Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing Positive RT-PCR Test Results in Patients Recovered From COVID-19 False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR An alternative workflow for molecular detection of SARS-CoV-2 -escape from the NA extraction kit-shortage A pneumonia outbreak associated with a new coronavirus of probable bat origin Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis Serological Assays for SARS Unauthorized reproduction of this article is prohibited. Infectious Disease: Benefits, Limitations and Perspectives Cross-reaction of sera from COVID-19 patients with SARS-CoV assays Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) Agent-based models of inflammation in translational systems biology: A decade later In silico modeling: Methods and applications to trauma and sepsis Next-generation, personalised, model-based critical care medicine: a state-of-the art review of in silico virtual patient models, methods, and cohorts, and how to validation them Artificial Intelligence against COVID-19: An Early Review Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study Mapping the Landscape of Artificial Intelligence Applications against COVID-19 arXiv Extracting possibly representative COVID-19 Biomarkers from X-Ray images with Deep Learning approach and image data related to Pulmonary Diseases COVIDX-Net: A Framework of Deep Learning Classifiers to Diagnose COVID-19 in X-Ray Images. arXiv Unauthorized reproduction of this article is prohibited COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model COVID-19: combining antiviral and anti-inflammatory treatments Artificial intelligence and machine learning to fight COVID-19 An integrated clinico-metabolomic model improves prediction of death in sepsis Genome-wide expression profiling in pediatric septic shock Unique transcriptomic response to sepsis is observed among patients of different age groups Proteolysis in septic shock patients: plasma peptidomic patterns are associated with mortality Characterization of a metabolomic profile associated with responsiveness to therapy in the acute phase of septic shock An Innovative Approach for The Integration of Proteomics and Metabolomics Data In Severe Septic Shock Patients Stratified for Mortality A longitudinal study highlights shared aspects of the transcriptomic response to cardiogenic and septic shock Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. medRxiv 226 Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Hong Kong: a multicentre retrospective observational cohort study Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates The phylogeny is rooted relative to early samples obtained from Wuhan, China. Thereafter, a sustained human-to-human transmission with the first case outside of China (Thailand) was confirmed on We thank Michaela Steiner for the critical assessment and the suggestions to the section -SARS-CoV-2 diagnosis and optimization of testing‖.